Importantly, modulation of these genes may attenuate several mechanisms associated with Doxo resistance in MCF7 including (a) increased drug efflux [59], (b) cell death resistance (through alterations in ER-α and/or NF-κB pathways) [60, 61], (c) epithelial-to-mesenchymal transition [62], (d) the enrichment of cancer stem cell-like phenotype [60, 63], and (e) autophagy [43]. The gene discussed is ESR1; the disease is cancer.